Book a demo

Chemical intelligence powered by cypris.ai

Semaglutide

18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid · also: Wegovy, Ozempic, Rybelsus, semaglutida, semaglutidum, Sermaglutide

FormulaC187H291N45O59
Mol. weight4113.641
PubChem CID56843331
InChIKeyDLSWIYLPEUIQAV-CCUURXOWSA-N
SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
8,537Patents
1,345Research papers
4,233Patents - last 3 years
835Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Sanofi SA881
2Novo Nordisk AS449
3Sanofi Aventis Deutschland GmbH350
4SHL Medical AG284
5Sanofi Aventis France269
6Pfizer Inc268
7Pfizer Corp SRL251
8Merck Sharp and Dohme LLC225
9Boehringer Ingelheim International GmbH174
10Gilead Sciences Inc167

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations5,607
2A61PTherapeutic activity (drug indications)5,263
3C07KPeptides2,213
4A61MDevices for introducing media into the body1,930
5C07DHeterocyclic compounds1,889
6C12NMicroorganisms, enzymes606
7G16HDigital health, healthcare informatics315
8C07BGeneral methods of organic chemistry300
9C07CAcyclic and carbocyclic compounds294
10G01NInvestigating / analysing materials275

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Preparation method of semaglutide2015HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD.32
Solid synthetic method of semaglutide2014Hybio Pharmaceutical Co., Ltd.23
High-expression semaglutide precursor recombinant engineering bacterium and construction method thereof2021Beijing Huizhiheng Biological Technology Co Ltd18
Semaglutide purifying method2016Hybio Pharmaceutical Co., Ltd.17
Preparation method of semaglutide and intermediate of semaglutide2016Hybio Pharmaceutical Co., Ltd.11

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Advanced Drug Delivery Systems1
2Diabetes Treatment and Management1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Ildiko LingvayThe University of Texas Southwestern Medical Center33
2Søren RasmussenNovo Nordisk (Denmark)21
3Melanie J. DaviesUniversity of Leicester18
4Subodh VermaSt. Michael's Hospital17
5A. Michael LincoffCleveland Clinic Lerner College of Medicine15
6Andrei‐Mircea CatarigNovo Nordisk (Denmark)15
7Barry A. BorlaugMayo Clinic12
8Barnaby HuntFreiwillige Akademische Gesellschaft11
9Mikhail KosiborodSaint Luke's Hospital9
10Stephen C. BainSwansea University9

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

TitleYearCited byTopic
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes20166581Diabetes Treatment and Management
Once-Weekly Semaglutide in Adults with Overweight or Obesity20214471Diabetes Treatment and Management
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes20232539Diabetes Treatment and Management
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis20201864Liver Disease Diagnosis and Treatment
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes20211847Diabetes, Cardiovascular Risks, and Lipoproteins

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of semaglutide?

Semaglutide has the molecular formula C187H291N45O59 with a molecular weight of 4113.641 g/mol. Its InChI Key is DLSWIYLPEUIQAV-CCUURXOWSA-N.

Which organizations hold the most patents related to semaglutide?

Sanofi SA holds the largest patent portfolio with 881 patents, followed by Novo Nordisk AS with 449 patents and Sanofi Aventis Deutschland GmbH with 350 patents.

What are the most heavily cited research papers on semaglutide?

The most cited paper is 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes' with 6538 citations, followed by 'Once-Weekly Semaglutide in Adults with Overweight or Obesity' with 4396 citations, and 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes' with 2539 citations.

What patent classification codes are most common in semaglutide-related patents?

The most prevalent CPC classifications are A61K (pharmaceutical preparations) with 5602 patents, A61P (pharmaceutical activity classification) with 5259 patents, and C07K (organic compounds containing amino acid or peptide groups) with 2213 patents.

How has patent filing activity for semaglutide changed over time?

Patent filing activity has grown substantially in recent years, increasing from 174 patents in 2016 to 1823 patents in 2024. The most significant growth occurred between 2021 and 2023, with 523, 1205, and 1461 patents filed respectively in those years.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial